ZA200403933B - Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs - Google Patents
Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs Download PDFInfo
- Publication number
- ZA200403933B ZA200403933B ZA200403933A ZA200403933A ZA200403933B ZA 200403933 B ZA200403933 B ZA 200403933B ZA 200403933 A ZA200403933 A ZA 200403933A ZA 200403933 A ZA200403933 A ZA 200403933A ZA 200403933 B ZA200403933 B ZA 200403933B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- composition
- substance
- pharmaceutical composition
- formula
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 115
- 241000282472 Canis lupus familiaris Species 0.000 title claims description 32
- 241000282326 Felis catus Species 0.000 title claims description 26
- 208000035143 Bacterial infection Diseases 0.000 title claims description 15
- 208000022362 bacterial infectious disease Diseases 0.000 title claims description 15
- -1 cephalosporin compound Chemical class 0.000 title claims description 15
- 238000009472 formulation Methods 0.000 title description 75
- 229930186147 Cephalosporin Natural products 0.000 title description 24
- 229940124587 cephalosporin Drugs 0.000 title description 24
- 150000001875 compounds Chemical class 0.000 claims description 142
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 32
- 229930006000 Sucrose Natural products 0.000 claims description 31
- 239000005720 sucrose Substances 0.000 claims description 31
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 28
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 28
- 239000003755 preservative agent Substances 0.000 claims description 24
- 239000011734 sodium Substances 0.000 claims description 24
- 235000002639 sodium chloride Nutrition 0.000 claims description 23
- 239000004067 bulking agent Substances 0.000 claims description 22
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 20
- 229960002216 methylparaben Drugs 0.000 claims description 20
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 14
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 14
- 229960003415 propylparaben Drugs 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 230000002335 preservative effect Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 8
- 150000005846 sugar alcohols Polymers 0.000 claims description 8
- 150000008163 sugars Chemical group 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 210000004872 soft tissue Anatomy 0.000 claims description 5
- 210000001635 urinary tract Anatomy 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000011009 potassium phosphates Nutrition 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- 235000011008 sodium phosphates Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000243 solution Substances 0.000 description 41
- 159000000000 sodium salts Chemical class 0.000 description 36
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 26
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 21
- 150000001780 cephalosporins Chemical class 0.000 description 20
- 238000004108 freeze drying Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 244000005700 microbiome Species 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000007979 citrate buffer Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 238000007792 addition Methods 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 229960004217 benzyl alcohol Drugs 0.000 description 7
- 235000019445 benzyl alcohol Nutrition 0.000 description 7
- 150000003445 sucroses Chemical class 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000008228 bacteriostatic water for injection Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 4
- 229960001950 benzethonium chloride Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 3
- 241000606856 Pasteurella multocida Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 241000191980 Staphylococcus intermedius Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 125000000185 sucrose group Chemical group 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 239000005660 Abamectin Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 101000807541 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 24 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000025769 Mucor luteus Species 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000605894 Porphyromonas Species 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- 208000006311 Pyoderma Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241001312524 Streptococcus viridans Species 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- 102100037176 Ubiquitin carboxyl-terminal hydrolase 24 Human genes 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229960003016 cefoxitin sodium Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 229940051027 pasteurella multocida Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 description 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 239000005899 Fipronil Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 239000005906 Imidacloprid Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 description 1
- 229940123930 Lactamase inhibitor Drugs 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 239000005912 Lufenuron Substances 0.000 description 1
- 208000010315 Mastoiditis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010037294 Puerperal pyrexia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229950008167 abamectin Drugs 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical class S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 1
- 229960003997 doramectin Drugs 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- JUHMHPOXZAYYJP-UHFFFAOYSA-N ethyl 5-amino-1-(4-methylphenyl)sulfonylpyrazole-4-carboxylate Chemical class NC1=C(C(=O)OCC)C=NN1S(=O)(=O)C1=CC=C(C)C=C1 JUHMHPOXZAYYJP-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940013764 fipronil Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229940056881 imidacloprid Drugs 0.000 description 1
- YWTYJOPNNQFBPC-UHFFFAOYSA-N imidacloprid Chemical compound [O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1 YWTYJOPNNQFBPC-UHFFFAOYSA-N 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002334 isothermal calorimetry Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229940006487 lithium cation Drugs 0.000 description 1
- 229960000521 lufenuron Drugs 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229960002531 marbofloxacin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 description 1
- 229960002245 selamectin Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
FORMULATIONS COMPRISING A CEPHALOSPORIN COMPOUND AND THEIR USE TREATING
BACTERIAL INFECTIONS IN CATS AND DOGS
This invention relates to stable lyophilized formulations containing an antibacterial alkali metal salt of a cephalosporin compound, Compound |, wherein M* is a cation, Na*, K* or Li* (hereinafter "Compound I). In particular, the invention relates to stable lyophilized formulations of Compound |, wherein M* is Na*, (6R,7R)-7- [[(22)-(2-amino-4-thiazolyl)(methoxyimino) acetylJamino]-8-oxo-3-[(2S)-tetrahydro-2- - furanyl]-5-thia-1 -azabicyclo[4.2.0]Joct-2-ene-2-carboxylic acid, monosodium salt. The invention also relates to aqueous formulations of Compound I. /
N—O
HN NUH
* ~~ S
S 0
N. A Oo 0) 07 "0
M+
The invention is also directed to methods for treating bacterial infections in dogs and cats by administering a compound of Formula 1.
Cephalosporins are widely used and therapeutically important antibiotics.
The compounds of Formula | are broad spectrum cephalosporin antibacterials and are, therefore, useful in the treatment of bacterial infections in animals. (US 6,020,329, Col. 1, lines 13-14). In particular, Compound | is targeted for dogs and cats with indications for treatment of bacterial infections of the skin, soft tissue, periodontal and urinary tract.
Compound |, wherein M is Na*, and the preparation thereof, are disclosed in
U.S. Patent Nos. 6,001,997, 6,020,329 and 6,077,952. The text of the aforementioned patents and all other references cited in this specification are hereby incorporated by reference in their entirety.
U
Cephalosporin formulations are generally, however, unstable and a variety of different methods exist to increase stability including, inter alia, the adjustment of pH, crystallization, lyophilization, and the addition of stabilizers, such as sugars.
Cephalosporins may be somewhat stabilized within a certain pH range. The optimum pH range varies widely and is unpredictable for different classes of cephalosporins, requiring experimentation and stability tests. For example, Nassar et al., U.S. Pat. No. 5,401,842, disclosed formulations of crystalline cefepime salt buffered with trisodium orthophosphate, sodium bicarbonate, sodium citrate, N- methyl-glucamine and L(+) arginine to a pH of 3.5 to 7.0.
K.A. Conners et al. disclose that cephalothin has a broad stability range from a pH of between 2 to 8. Cepharadine, however, stabilizes at a more acidic pH between 1 to 5. Stability for Cefotaxime is achieved in the pH range of 310 7. (K.A. Connors, et al. Chemical Stability of Pharmaceuticals, John Wiley & Sons,
New York, 1986, p305).
In some cases, cephalosporin formulations were stabilized by crystallization and lyophilization. For example, Gotschi, U.S. Pat. No. 5,138,066, describes formulations for parenteral administration as lyophilizates or dry powders for dilution with pharmaceutical carriers such as water or isotonic saline.
Bornstein et al, U.S. Pat. No. 4,002,748, disclose methods of preparing essentially amorphous cefazolin by utilizing certain lyophilization techniques, while
Daugherty, EP 0327364, describes a lyophilization method to prepare formulations of a crystalline solvate of a 1-carbacephalosporin.
Some cephalosporins may be stabilized by addition of a variety of different sugars. Whether a certain sugar will stabilize a particular cephalosporin, however, is unpredictable. Furthermore, the ratio of sugar to cephalosporin to achieve optimum stability is also unpredictable. For example, Shamblin et al. disclose that the stability of amorphous cefoxitin sodium was improved by a factor of two when co-lyophilized with sucrose. The stability of cefoxitin was not affected, however, when co-lyophilized with trehalose. S.L. Shamblin, B.C. Hancock, M.J.Pikal, The
Chemical Stability of Amorphous Cefoxitin Sodium in the Presence of Glassy
Stabilizers, AAPS Pharm. Sci. Vol. |, Issue 4, 1999.
Similarly, Shima et al., EP 0134568B1, disclose that sugar (glucose, fructose or maltose) or an alkali metal salt of a mineral acid or carboxylic acid ga stabilized a specific lyophilized cephalosporin ata 0.01:1 to 0.5:1 weight ratio of stabilizer:cephalosporin. Mannitol, however, was not effective in stabilizing the disclosed cephalosporin compound.
Likewise, Almarsson et al., Tetrahedron 56 (2000) 6877-6885, disclose that sucrose improved chemical stability of a beta-lactam compound at a sucrose/drug ratio of 0.1:1 t0 0.5:1.
Yoshioka, Y. et al., Pharm, Res. 17 (2000), 925-929, disclose the stability of cephalothin in the presence of dextran at a dextran/cephalothin ratio of 200:1.
Conversely, Hirai et al., U.S. Patent No. 4,418,058, disclose that an excess amount, greater than 1:1, of a variety of different sugars or sugar alcohols adversely affected chemical stability of cephalosporins. Good stabilizing results were obtained, however, when the amount of added sugar or sugar alcohol was 0.1 to 1 sugar/cephalosporin.
Consequently, one of ordinary skill in the art cannot, in general, predict whether the addition of a particular sugar to any particular cephalosporin will : : achieve stability. -Moreover, the optimum ratio of sugar:cephalosporin is also highly variable and unpredictable, absent experimentation. Furthermore, as discussed above, the optimum pH range of stability for a particular cephalosporin is also unpredictable. : :
A method of administration for Compound | is by parenteral administration.
Other modes of administration include oral and topical. (US 6,020,329, Col. 15, lines 1-2 Compound I is unstable, as both a solid and an aqueous solution.
Furthermore, Compound | is hygroscopic. Consequently, a formulation and : method for stabilizing Compound | would be a useful addition to the art.
In a first aspect, the invention provides a pharmaceutical composition comprising a compound of Formula |, /
N-O
HN NAH
: ~~ A Se
S o I
NZ 0
Oo oxi}
M+ wherein M* is Na*, K* or Li*, and an aqueous diluent, wherein the composition has a pH in the range of 5.0 to 8.0. in a preferred embodiment, the compound of Formula | is amorphous (6A,7R)-7-[[(2.2)-(2-amino-4-thiazolyl)(methoxyimino) acetyllamino]-8-0x0-3-{(25)- tetrahydro-2-furanyi}-5-thia-1 -azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt.
In a preferred embodiment, M* is Na* and the pH is 6.0 to 7.5.
In a preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable buifer.
In a more preferred embodiment, the buffer is carbonate, phosphate, citrate or acetate, and the pH within a range of 6.0 to 7.5.
Ina preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable bulking agent.
In a more preferred embodiment, the bulking agent is selected from sugars, polyalcohols, amino acids, polymers, polysaccharides or inorganic salts.
In a preferred embodiment, the sugars are selected from glucose, maltose, sucrose and lactose; the polyalcohols are sorbitol or mannitol; the amino acid is glycine; the polymer is polyvinylpyrrolidone; the polysaccharide is dextran; and the inorganic salts are sodium or potassium phosphates or sodium chloride.
<
In a preferred embodiment, the composition has a bulking agent/compound of Formula | ratio greater than 1.0, but less than 100.
In a more preferred embodiment, the ratio is greater than 1, but less than 10.
In a morr preferred embodiment, the bulking agent is sucrose and the composition has a sucrose/compound of Formula | ratio of 3. in another aspect, the invention is directed to a pharmaceutical composition comprising a compound of Formula |, /
N—O
HN NL H
IAs
S o I
N. ~~ (0) 0) 0” "0
M+ wherein M* is Na*, K* or Li*, an aqueous diluent and a pharmaceutically acceptable bulking agent. . in a preferred embodiment, the bulking agent is selected from sugars, polyalcohols, amino acids, polymers, polysaccharides or inorganic salts. :
In a more preferred embodiment, the sugar is selected from glucose, maltose, sucrose or lactose; the polyalcohols are sorbitol or mannitol; the amino acid is glycine; the polymer is polyvinylpyrrolidone; the polysaccharide is dextran; and the inorganic salts are sodium or potassium phosphates or sodium chloride.
In another embodiment, the composition has a bulking agent/compound of
Formula | ratio of greater than 1, but less than 10. :
In a preferred embodiment, M* is Na* and the bulking agent is sucrose, wherein the composition has a sucrose/compound of Formula | ratio of 3.
In a preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable buffer.
G
In a preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable preservative.
In a more preferred embodiment, the preservative is methylparaben, propylparaben, m-cresol, benzalkonium chloride, benzethonium chloride or benzyl alcohol, or a combination of two or more thereof. in a more preferred embodiment, the preservative is a combination of either (a) methylparaben, propylparaben and benzyl alcohol; or (b) methylparaben and m- cresol.
In another embodiment, the pharmaceutical composition further comprises a citrate buffer. in another aspect, the invention is directed to a pharmaceutical composition comprising a compound of Formula |,
N—O
H,N N / H
EEE NS
0]
N= (0) 0) 0) o}
M+ wherein M* is Na*, further comprising an optional pharmaceutically acceptable buffer, an optional pharmaceutically acceptable preservative, an optional pharmaceutically acceptable bulking agent and an aqueous diluent, wherein the composition has a pH of 6.0 to 7.5.
In a preferred embodiment, the buffer is citrate; the preservative is methylparaben, propylparaben, m-cresol, benzalkonium chloride, benzethonium chloride or benzyl alcoho! or a combination of two or more thereof; and the optional bulking agent is sucrose. in a preferred embodiment, the pharmaceutical composition comprises a compound of Formula |, prepared by lyophilizing the pharmaceutical composition as described above. in another aspect, the invention is directed to a kit comprising a) A therapeutically effect amount of a lyophilized pharmaceutical composition comprising a compound | of Formula I; /
N—O
HNN LH
J N S
S 0 I
N= 0)
Oo 0” "0
M+ b) An aqueous pharmaceutically acceptable diluent; and c) A first and second container means for containing the composition (1) and the diluent (2), wherein the first container is adapted to receive the diluent from the second container.
In another aspect, the invention is directed to a method of treating or preventing a condition caused by a bacterial infection in dogs and cats, comprising administering a therapeutically effective amount of a compound of Formula /
N—O
HN NL H
Crs 0) l
N= 0 oO 0” "0
M+ effective in treating such a condition.
In another aspect, the invention is directed to a method of treating or preventing a condition caused by a bacterial infection in dogs and cats, comprising administering a therapeutically effective amount of the composition described above.
g
In one embodiment, the condition is a skin, soft tissue or urinary tract bacterial infection.
In another embodiment, the condition or infection is caused by or complicated by Gram positive or Gram negative bacteria.
The term “about,” as used herein, is defined as a pH of 0.5 above or below the designated upper and lower pH units.
The term "aqueous pharmaceutically acceptable diluent’ means water or other pharmaceutically acceptable aqueous solutions containing one or more pharmaceutically acceptable excipients for use in making the compositions of the invention (e.g. isotonic solution of sodium chloride, water for injection with ethanol or phosphate, acetate or citrate buffer, and water for injection with benzyl alcohol).
The term “Na*,” as used herein, is defined as a sodium cation. ’
The term “K*,” as used herein, is defined as a potassium cation.
The term “Li*,” as used herein, is defined as a lithium cation. :
The term “composition”, as used herein, encompasses, inter alia, (1) solutions comprising Compound | or (2) dry lyophilized residues of such solutions.
The solutions may contain one or more optional agents which aid in stabilizing : : dissolved Compound | and/or that facilitate re-dissolution, upon reconstitution of the lyophile created after lyophilizing solution (1). Such optional agents include, inter alia, bulking agents, preservatives, and buffers, as further disclosed herein. : : The term “Compound I” is limited to the pharmaceutically acceptable alkali metal salts of Compound |, wherein M* is Na*, K* or Li*, and in particular, includes
Compound |, (6R,7R)-7-[[(22)-(2-amino-4-thiazolyl)(methoxyimino) acetyllamino]-8- ox0-3-[(2S)-tetrahydro-2-furanyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic - acid, monosodium salt), wherein M* is Na®.
The term “lyophilization” means the process of freeze-drying a composition as known in the art. “Lyophilized” and “freeze-dried” are used herein as synonyms.
The terms "pharmaceutical" and “pharmaceutically” and the like are meant to refer to applications in both human and veterinary fields.
Compound | is a broad spectrum cephalosporin antibacterial targeted for mammals, in particular, dogs and cats. The preparation of Compound | wherein M* is Na* (hereinafter the "sodium salt") is described in U.S. Patent Nos. 6,001,997,
6,020,329, 6077,952, as well as EP1178049A1; incorporated herein by reference in their entirety. The K*and Li* salts of Compound | may be prepared by one of ordinary skill in the art, as described in the preparation of the sodium salt of compound |, but substituting an appropriate K* or Li* salt.
The antibiotic compounds of the present invention are active against a wide range of organisms, including both Gram-negative organisms (e.g. E.coli), and
Gram-positive organisms, (e.g.S. aureus). (US 6,020,329, Col 17, lines 28-31).
Compound | can be used to treat, inter alia, bacterial infections of the skin, soft tissue and urinary tract. For example, conditions or infections caused by or : complicated by Gram positive and/or Gram negative bacteria are: canine pneumonia, feline pneumonia, canine pyoderma, feline pyoderma, pasteurellosis, pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis associated with infection by Staphylococcus spp. (Staphylococcus intermedius, Staphyloccus aureus), Escherichia coli, Streptococcus spp. (Beta Hemolytic Streptococcus spp.),
Pasteurella multocida, Bacteriodes spp., Fusobacterium spp., Porphyromonas spp.,
Prevotella spp., Peptostreptococcus spp., and Clostridium spp., uncomplicated skin and soft tissue infections, abscesses, osteomyelitis, and puerperal fever associated ‘with infection by Staphylococcus aureus, S. intermedius, coagulase-positive staphylococci, S. epidermidis, S. hemolyticus, Streptococcus ssp, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, uncomplicated acute urinary tract infections associated with infection by Staphylococcus ssp or E. coli.; odontogenic infection associated with infection by viridans streptococci; urinary tract infection in dogs and cats associated with infection by E. coli; skin and soft tissue infections in dogs and cats associated with infection by Staph. 05 epidermidis, Staph. intermedius, coagulase neg. Staph. or P. multocida; infections of the oral cavity in dogs and cats associated with infection by Alcaligenes spp.,
Bacteroides spp., Clostridium spp., Enterobacter spp., Eubacterium,
Peptostreptococcus, Porphyromonas, or Prevotella.
It was determined that the compounds of Formula |, as well as similar compounds disclosed in U.S. Patent Nos. 6,001,997, 6,020,329 and 6,077,952, exhibit an unexpectedly long half-life in dogs and cats, especially in view of comparable antibiotics. For example, Table | lists well-known antibiotics and their respective half-lives in different mammals, such as in mice, rats, dogs and cats.
TABLE 1: Half-life of Known Antibiotics 0.68 (PO 140) [24(FO0)
Ampicilin_______ | 084M 06a (M)
Cefamandole — los) los2(V)
Cephalordine — los(M) __ loo7(M) [ Cephalothin | 0.208 (IM 04M) [1.06(M) [Cephadrine | |0:82(PO 3.64 (PO
Oleandomycin____107(v) ____ loea(v) _ [153(V)
Tyosn | [04) 1.24 (V) 5 . (Cefpodoxime data from “Abstracts of the 1996 ICAAC™: Abstract 593. All other data compiled from: “CRC Handbook of Comparative Pharmacokinetics and
Residues of Veterinary Antimicrobials”, J. Edmond Riviere; Arthur L. Craigmill,
Stephen F. Sundiof CRC Press 1991; Routes of administration: "IV" - 10 intravenous; "IM" = intramuscular; "PO" = per os; "SC" = subcutaneous)
A number of cephalosporin derivatives, including compounds of Formula I, were disclosed in International Patent Application publication number WO 92/01696 and by Bateson et al in The Journal of Antibiotics, Feb.1994, vol.47, no.2, at pages 253-256. Various mouse data are also disclosed in the latter paper. Both of these publications are herein incorporated in their entirety.
In particular, following administration of the compound of Formula II, the half- life in the mouse and rat were determined to be 2.2 and 3.9 hours, after per os administration, respectively. Unexpectedly, however, in dogs and cats the half-life was in both cases dramatically increased, as is demonstrated below in Table il. /
N—O
H.N N / H
BORN
Oo i
NA O
0] 0) OR
H
TABLE 2: Half-life in Dogs and Cats
Expormeny | Specles. “Rows | Dose’ |. Compound. | Halkife =
STR ee (glk) fe at es oo : 1 Iv Compound of 6.9 days
Formula |, M" =Na 2 SC Compound of 4.7 days
Formula |, M* =Na 3 Dog 1 Compound lf, R = 6.0 days pivaloyloxymethyl 4 Cat EEE Compound of 6.3 days
Formula i, M" =Na
Note [1] Dose expressed as corresponding free acid : i.e. M* =H. Concentrations measured w.r.t. free acid. : .
EXPERIMENTAL DETAILS a. Pharmacokinetics
Experiment 1: Intravenous Dog
A male dog was dosed intravenously with an aqueous solution of Compound
I. Blood plasma was sampled at times up to 28 days post dosing. Plasma samples were extracted and assayed to determine the concentration by both bioassay and
HPLC as follows: 1mL of plasma (or standards of spiked dog plasma) were acidified to a pH of less than 3 with hydrochloric acid, then shaken with 26 mL of ethyl acetate. The layers were separated by centrifugation. 22 mL of the organic layer was transferred into a fresh container and 2.0 mL of 0.1 M phosphate buffer, pH 7.0, was added.
After shaking and centrifugation, the aqueous phase was recovered and assayed.
Following processing, samples (and standards) were assayed by hole-in-the-plate microbiological bioassay on large plates (200 mL Mueller Hinton agar) seeded with
M. luteus. Samples were also assayed by HPLC (uBondapk —C18 column eluted with acetonitrile- 0.05M sodium acetate pH 5.0, 15:85, with UV detection at 256nm).
Good agreement was obtained between the two assay methods, and the half-life was calculated from bioassay results using standard pharmacokinetic methods.
Experiment 2: Subcutaneous Dog
Two dogs were dosed with compound of Formula | by subcutaneous injection. - Blood plasma was sampled at times up to 28 days post-dosing. Plasma samples and appropriate standards were prepared by deproteination by the addition of an equal volume of acetonitrile and centrifugation (3000 r.p.m. for 10 min.). Supernatant
Va was assayed by a specific HPLC method to determine the concentration (uBondapk —C18 column eluted with acetonitrile- 0.05M sodium acetate pH 5.0, 15:85, at 1.0 mL/min with UV detection at 256nm). Pharmacokinetic parameters were calculated using the program PCNONLIN.
Experiment 3: per os Dog
Six dogs were dosed orally with the pivaloyloxymethyl-ester pro-drug, compound of Formula ll, and the resulting plasma concentrations were determined by both bioassay and HPLC. Following dosing, blood plasma was sampled up to 696 hours (29 days). Plasma samples and appropriate standards (1mL) were first acidified to a pH less than 3.0 with hydrochloric acid then shaken with 30 mL ethyl acetate. The layers were separated by centrifugation then 25mL of the organic layer was removed. 2mL of 0.1M phosphate buffer pH 7.0 was added to the ethyl acetate and shaken to effect a back extraction. After separation of the layers, the aqueous phase was removed and used for the assays. Following processing, samples (and standards) were assayed by hole-in-the-plate microbiological bioassay on large plates (200 mL Mueller Hinton agar) seeded with M. luteus. Samples were also assayed by HPLC (uBondapk —C18 column eluted with acetonitrile- 0.05M sodium acetate pH 5.0, 15:85,at 1.5 mL/min with UV detection at 256nm). There was good agreement between the two assay methods (r=0.9716) half-life was calculated from the bioassay data.
Experiment 4: Subcutaneous Cat
Four cats were dosed at 8 mg/kg by subcutaneous injection of Compound I.
Blood samples were taken at intervals to 35 days post-dosing and the plasma assayed to determine the concentration of the corresponding free acid by
HPLC/MS/MS. Plasma samples (100 mL) were aliquotted into centrifuge tubes, then 400 mL of acetonitrile was added. Following vortexing (60 sec.) and centrifugation (20,800 x g for 10 minutes), 0.450 mL of the supernatant was transferred into clean centrifuge tubes, and evaporated to dryness at approximately 50°C under N,. Dried samples were reconstituted in 0.100 mL of mobile phase (15/85 v/v acetonitrile/10 mM HCO,NH,, pH 3.0), vortexed for 1 minute, centrifuged at 3,000 rpm for 2 minutes, and transferred to an autosampler vial. Single replicates of plasma were analyzed by LC-MS/MS for concentration of compound. Sample analysis was performed on a SCIEX API 365 or 3000 HPLC/MS/MS system. The column effluent was connected to a Turbo-ionspray source set at 4500 V. The collision gas was set to a value of 3. Positive ions were generated in the source and sampled through an orifice into the quadrupole mass filter. The mass spectrometer was adjusted to monitor the precursor and product ions as follows: m/z 454.0 -> m/z 241.0. Half-life was calculated using pharmacokinetic program WINNONLIN v2.1 and determined to be 8.39 +/- 0.97 days. b. Efficacy in an experimentally induced skin infection model study, five out of six dogs had complete clearance of Staphylococcus intermedius 15 days after a single administration of 8 mg/kg of the Compound I.
In a separate study, following a single administration of 8 mg/kg Compound to healthy dogs, there was a significant reduction of the populations of pathogenic
Staphylococci for four weeks compared to non-treated control animals.
In an experimentally induced abscess model study in cats, there was a substantial reduction in the numbers of Pasteurella multocida, Clostridium perfringens, and Bacteriodes fragilis bacteria 14 days after a single administration of 8 mg/kg Compound | So Co
The above half-life results, together with the potency of the compounds of
Formula |, demonstrates that one administration of an equivalent of ca. 4-12 mg/kg of
Compound |, (e.g.Na salt of compound of Formula I), given by injection (e.g. intramuscularly, subcutaneously or intravenously), to a cat or dog would advantageously provide an efficacious concentration for 7-21 days. This represents a novel and very convenient treatment regime for veterinary practitioners and cat and dog owners alike.
It has been determined, however, that Compound | is unstable both as a solid and a liquid. In evaluating possible formulations, stability experiments were conducted. As used herein, “stable” or “stabilized” means less than or equal to about 10% decomposition of Compound I. .
While many cephalosporins may be stabilized by crystallization, it has been determined that Compound | is not particularly amenable to crystallization techniques on a commercial scale. Consequently, Compound | is in an amorphous state and is hygroscopic. It was determined that optimal long-term stability of
Compound | is achieved at a low residual water content. Accordingly, lyophilization of formulations of Compound | provide preferred stability.
as
With respect to the present invention, stable formulations of Compound were developed, overcoming the inherent stability problems previously hampering long-term storage goals. It was determined that Compound | could be stabilized and formulated into injectable preparations by formulating Compound | with an aqueous pharmaceutically acceptable diluent, such that the pH is in the range of about 5.0 to about 8.0.
For example, formulations are prepared by dissolving a therapeutically effective amount of the sodium salt of Compound | in an aqueous pharmaceutically acceptable diluent and adjusting the pH, if necessary, to within the range of about 5.0 to about 8.0. Alternatively, the free acid form of Compound | (i.e. the carboxylate, instead of the salt) may be utilized as starting material. A suspension or solution of the free acid may be titrated with, for example, sodium hydroxide, forming the sodium salt of Compound |. Adjustments to pH may be conducted as described above.
Aliquots of the resulting solution, the quantity of which is dependent upon the ultimate desired reconstituted concentration of Compound |, are clarified and sterile filtered and aseptically transferred to containers appropriate for lyophilization, (e.g. vials), and partially stoppered with lyo-stoppers. As described hereinafter, the formulation is cooled to freezing, subjected to lyophilization in a : manner conventional per se in the art and hermetically capped, forming a stable, dry lyophile formulation. In a preferred embodiment, the composition has a low - residual water content, less than 1% by weight, based on the weight of the lyophile.
In a more preferred embodiment, the composition has a residual water content level of less than 0.5% by weight. :
As used herein, a “therapeutically effective amount” for a dosage unit may typically about 50 to about 500 mg of active ingredient. (US 6020,329; Col 16, line 3). The dose may vary, however, depending on the species, variety, etc. of animal to be treated, the severity and type of infection and the body weight of the animal.
Accordingly, based upon body weight, typical dose ranges of the active ingredient may be from about 0.01 to about 100 mg per kg of body weight of the animal.
Preferably, the range is from about 1 to about 20 mg per kg of body weight, and more preferably, from about 4 to about 12 mg per kg of body weight. (PCS10965; p7, lines7-11)
ZS
The veterinary practitioner, or one skilled in the art, will be able to determine the dosage suitable for the particular individual patient, which may vary with the species, age, weight and response of the particular patient, as well as the bacterial species involved. The above dosages are exemplary of the average case.
Accordingly, higher or lower dosage ranges may be warranted, depending upon the above factors, and are within the scope of this invention.
Compounds of Formula | may be administered either alone or in combination with one or more agents used in the treatment or prophylaxis of disease or in the reduction or suppression of symptoms. Examples of such agents (which are provided by way of illustration and should not be construed as limiting) include antiparasitics, eg arylpyrazoles such as fipronil, lufenuron, imidacloprid, avermectins (eg abamectin, ivermectin, doramectin, selamectin), milbemycins, organophosphates, pyrethroids; antihistamines, eg chlorpheniramine, trimeprazine, diphenhydramine, doxylamine; antifungals, eg fluconazole, ketoconazole, itraconazole, griseofulvin, amphotericin B; antibacterials, eg enroflaxacin, marbofloxacin, ampicillin, amoxycillin; anti-inflammatories eg prednisolone, betamethasone, dexamethasone, carprofen, ketoprofen; steroids or other antipruritic agents; dietary supplements, eg gamma- linoleic acid; and emollients. Therefore, the invention further provides for uses, etc., of compounds of formula (1) and one or more selected compounds from the above list as a combined preparation for simultaneous, separate or sequential use in the treatment of diseases or conditions according to the invention.
The composition of the formulations may optionally contain auxiliary ingredients, as known in the art, such as buffers, bulking agents, diluents, co- solvents, solvents, preservatives, chelating agents, antioxidants, tonicity adjusters, whose presence may help to provide a rapidly soluble freeze-dried product or extend the storage time of the formulation.
An example of a possible solvent and co-solvent is ethanol. An example of a chelating agent is ethylenediaminetetraacetic acid. An example of an antioxidant is ascorbic acid. An example of a tonicity adjuster is dextrose. Furthermore, the compound of Formula | may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a B-lactamase inhibitor may be employed. (US 6,020,329; Col 16, lines 16-18)
Unlike most cephalosporins with typical broader pH ranges of stability, it was determined that formulations of Compound } with or without various buffers have a relatively narrow range of stability between a pH of about 5.0 to about 8.0. In particular, and in a preferred embodiment, optimal solution and solid state stability are achieved at a pH of about 6.0 to about 7.5. Adjustment of pH may be accomplished by either titrating to the desired pH range with, for example, a 10% solution of sodium hydroxide or hydrochloric acid, or using an appropriate buffer. Typical buffers include phosphate, acetate, citrate, carbonate, and glycine. In a preferred embodiment, phosphate is used as a buffer. In a more preferred embodiment, citrate is used as a buffer.
The water-soluble bulking agent suitable for use in the present invention can be any of the pharmaceutically acceptable inert solid materials typically used for lyophilization. Bulking agents may improve stability and/or provide a more rapidly soluble freeze-dried product. Such bulking agents include, for example, sugars such as glucose, maltose, sucrose and lactose; polyalcohols such as sorbitol and mannitol; amino acids such as glycine; polymers such as polyvinylpyrrolidone; polysaccharides such as dextran; certain inorganic salts such . as sodium or potassium phosphates, or sodium chloride.
The ratio of the weight of the bulking agent to the weight of Compound used in the compositions of the present invention should generally be within the range of from about 0.01 to about 100, depending upon the bulking agent utilized.
In a preferred embodiment, polyhydroxy compounds are the bulking agent of choice. In a more preferred embodiment, sucrose is the bulking agent and was found to stabilize the sodium salt of Compound | when co-lyophilized therewith.
The optimum ratio of sucrose/Compound I, however, was unpredictable, absent experimentation. For example, it was determined that, compared to 05 formulations without sucrose additions, a relatively small amount of sucrose (e.g. sucrose/sodium salt of Compound | ratio of 0.4) increased the extent of degradation of the sodium salt of Compound I. On the other hand, a sucrose/sodium salt of Compound | ratio of 1 exhibited similar stability as formulations wherein no sucrose was added. Ratios greater than 1.0, however, increased the stability of formulations of the sodium salt of Compound |. Ina preferred embodiment, the sucrose/sodium salt of Compound | ratio ranges from greater than 1.0 to about 10. In an even more preferred embodiment, the sucrose/sodium salt of Compound | ratio is about 3.
Higher sucrose/Compound ratios may be utilized. A high sucrose concentration is limited, however, by practical considerations of viscosity of high concentrated solution, impacting syringibility of the reconstituted solution.
Furthermore, high sucrose concentrations may create injection site intolerance for injectable preparations. As a general rule, viscosity of 25-30 mPa-s (millipascals - second), wherein “” is defined as “multiplied by”, can be considered as an upper limit for injectable preparations in the pharmaceutical industry. This translates to an approximate maximum 60% sucrose solution at 40°C. (M.Mathlouthi, J.
Génotelle, in: M.Mathlouthi, Sucrose. Properties and Applications, Blackie
Academic & Professional, London, 1995, p.1 37). For example, if the concentration of Compound | in solution is 6% by weight, the acceptable sucrose/Compound ratio would be 10:1. If Compound | concentration is 3%, the acceptable sucrose/Compound | ratio would be 20:1. These are but two examples of many possible ratios.
Antimicrobial preservatives are frequently added to pharmaceutical formulations to prevent microbial contamination. As used herein, the word “preservative” means a compound, or combination of compounds, added to prevent - or inhibit the growth of micro-organisms which could present a risk of infection or degradation of the medicinal product. Generally, the level of efficacy obtained varies according to the chemical structure of the preservative, its concentration and the physical and chemical characteristics of the medicinal product (especially pH).
The design of the pack and the temperature at which the product is stored will also affect the level of activity of any antimicrobial preservatives present. Useful preservatives may include m-benzoic acid and its salts, sorbic acid and its salts, alkyl esters of parahydroxybenzoic acid, phenol, chlorobutanol, benzyl alcohol, thimerosal, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, m-cresol and chlorocresol. Mixtures of the aforementioned preservatives may also be employed.
In the present invention, formulations of Compound | containing antimicrobial preservatives were effective in satisfying United States Pharmacopeia (hereinafter “USP”) criteria for antimicrobial effectiveness. In particular, various formulations of the following preservatives were found to satisfy USP criteria, for example, methyl paraben, propylparaben, m-cresol and benyzl alcohol. To satisfy
European Pharmacopeia (hereinafter “EP”) criteria for antimicrobial effectiveness,
however, other preservatives were more appropriate (e.g. benzethonium chloride and combinations of several preservatives such as methylparaben, propylparaben and benzyl alcohol, in one combination, and methyl paraben and m-cresol in another combination.
Formulations of Compound | can be isolated by drying, preferably by lyophilization as known in the art. Usually the lyophile formulations are produced with ampule lyophilization, vial lyophilization, tray lyophilization, or like conventional methods by cooling the formulations at subzero temperature to freezing. The frozen material is then dried under vacuum by subliming the water component originally contained in the solution as a solvent, thus leaving a solid lyophilized cake. Thus, for example, the excipients described above, Compound |, or the pharmaceutically acceptable salt of Compound |, are successively dissolved under stirring in a suitable amount of water for injections. Then, further water is added to reach the desired final volume. The resulting solution is clarified, sterile filtered and aseptically distributed in sterile containers (e.g. vials) of desired capacity. Freeze- drying the solution is then performed and the vials are hermetically sealed according to conventional procedures. .
The lyophilized drug product is amorphous Compound |, and more preferably the sodium salt thereof. When a product solution is required, it can be reconstituted by dissolving the dry formulation in water for injection, bacteriostatic water for injection or another pharmaceutically acceptable diluent (e.g. isotonic solution of sodium chloride, water for injection with ethanol or citrate buffer, and bacteriostatic water for injection with benzyl alcohol) in an amount sufficient to generate a solution of the required strength for parenteral administration to patients.
An amount of Compound | may be administered such that the composition provides the desired therapeutical effect as disclosed in U.S. Patent Nos. 6,001,997, 6,020,329 and 6,077,952. The injectable reconstituted solutions of the invention may be administered, according to a variety of possible dose schedules.
To confirm the advantageous effects of the present invention, the sodium salt of Compound |, was formulated into lyophilized injectable preparations and stability of the formulations was measured.
The examples below are intended to illustrate particular embodiments of the invention and are not intended to limit the specification, including the claims, in any manner.
A. Stabilization of lyophilized formulations by pH adjustment.
The formulations described in Tables 3-6, demonstrate the increased instability of compositions, both buffered and unbuffered, outside the pH range of about 5.0 to about 8.0. As set forth below in Tables 3 and 4, the sodium salt of
Compound | was dissolved in either deionized water or in citrate buffer solutions at 50 mg/mL.
For formulations 1-5, solution pH was adjusted with a 10% solution of hydrochloric acid after dissolution of the sodium salt of Compound | (TABLE 3).
For formulations 6-13, a buffered solution was prepared with citrate and adjusted : with a 10% sodium hydroxide solution, upon which the sodium sait of Compound was dissolved therein (TABLE 4). One mL aliquots of solutions of the sodium salt of Compound | were filled in 10 mL vials, and lyophilized using a FTS Kinetics freeze dryer (FTS Systems, Stone Ridge, New York). During lyophilization, the compositions were frozen using a two-step freezing protocol (at -25°C and -40°C), followed by primary drying at -27°C for approximately 22 hours, followed by a secondary drying with increased steps of temperature to 02C, 25°C and 50°C. The pressure during primary and secondary drying was set at 60 millitorr.
Examples of the solution preparation procedures are given below.
TABLE 3. Composition of formulations with HCI.
Formulation # | Compound 1 (mghial : - : 1 | so | + | 35 2 | Bs | + | 39 3 | s0 | + [ 41 4 | so [+ | 61 os 5 | ss [ - | 60 “4+” sign means that HC! was added to the formulation whereas “* sign indicates that HCl was not added.
Te
TABLE 4. Composition of formulations with Citric Acid.
Formulation # | Compound mg mg) — 6 | 50 | 96 | 50 7 | 50 | 96 | 55] 8 | 50 | 96 | 57 9 | 50 | 96 | 60 10 | 50 | 96 | 62 11 | 50 | 96 | 65 2 | 50 | 96 [68] — 13 | so | 96 | 70 14 | s0 | - [61] *pH of the solutions were adjusted to the specified values with 10% sodium hydroxide solution prior to lyophilization.
The samples were stored at 40°C for 12 weeks. The remaining amount of
Compound | was then measured by reverse-phase High Pressure Liquid
Chromatography (“HPLC”), using a Waters (Milford, MA) HPLC system with an
Ultraviolet (“UV”) detector set at 256 nm and a Kromasil C4 column (MetaChem
Technologies Inc., Torrance, CA). A gradient method was utilized with mobile phase
A consisting of 9:1 ratio v/v 0.025M sodium phosphate buffer solution, pH 6.5: acetonitrile, and mobile phase B consisting of 4:6 ratio v/v 0.025M sodium phosphate buffer solution, pH 6.5: acetonitrile. ‘
Degradation results are reported at Tables 5 and 6 as percentage (%) of initial purity of Compound I. Degradation of the formulation after 18 months storage at a controlled room temperature of 25°C (i.e. typical shelf storage conditions) was calculated using the pseudo-zero order model and the Arrhenius equation with an activation energy of 10 kcal/mol (e.g., K.A. Connors, Chemical Kinetics, 1990, VCH : 20 Publishers, Inc., New York). At this activation energy, the degradation rate constant at 40°C (Kao) is equal to 2.27*kes (kes is the degradation rate constant at 25°C). A person of ordinary skill in the art would appreciate the reasonableness of this assumption, based on data reported by Pikal et al. for other amorphous : cephalosporin compounds wherein, Ks=2.2"Kos. (M.J.Pikal, K.M. Dellerman, Stability testing of pharmaceuticals by high-sensitivity isothermal calorimetry at 25°C: cephalosporins in the solid and aquesous solution states, Int. J. Pharm. 50 (1989) 233-252).
PCT/IB02/04743
As set forth in Table 5, formulations 4 and 5 (respectively, pH of 5.1 and 6.0, from Table 3) had an acceptable long-term stability, (i.e. degradation after 18 months at 25°C is less than 10%). Formulations with a pH less than or equal to 4.1, however, demonstrated degradation at greater than 10%, which is typically unacceptable in the pharmaceutical industry for pharmaceutical products. As demonstrated in Table 4, the optimal stability for formulations utilizing a citrate buffer, however, was between pH of about 6.0 to about 7.0.
TABLE 5. Percent Compound | after 12 weeks storage at 40°C and estimated shelf life at controlled room temperature 25°C
Formulation # | 12 weeks | % Degradation | % Degradation® (40°C) after 12 weeks | after 18 months (40°C 25°C — 1 | ets | 87 [| 19 — 2 | a3 | 57 | 15 — 4 | oe | a1 | 8 5 | or2 | 28 | 7 * Calculated as described in the text
TABLE 6. Percent Compound | after 12 weeks storage at 40°C and estimated shelf life at controlled room temperature 25°C
Formulation # | 12 weeks | % Degradation | % Degradation® (40°C) after 12 weeks | after 18 months 40°C 25°C — 6 | ors | 25 [7 — 7 | eo | 20 | 5 — 8 | ose | 1a | 4 9 | e87 | 13 | 038 — 10 | ee | 11 | 03 — 41 | 91 | oe | 2 12 | e2 | 08 | 2 — 13 | e1 | 08 | 2 — 14 | 992 | 08 | 2 * Calculated as described in the text
Examples of solution preparation for the above stability studies of lyophilized formulations are with specific concentrations as follows: 21
AMENDED SHEET
Example 1
Formulation without pH Adjustment 1.0453 grams of the sodium salt of Compound | were dissolved in 20.0 mL de-ionized water. One mL aliquots of the resulting solution were transferred to 10-mL vials, partially stoppered with lyo-stoppers, lyophilized and hermetically capped, as described hereinabove.
Example 2
Formulation with pH Adjusted by HC! 0.5085 grams of the sodium salt of Compound | were dissolved in 10.0 mL de-ionized water. The solution was titrated with 0.1 N hydrochloric acid to pH 3.87.
One mL aliquots of the resulting solution were transferred to 10-mL vials, partially stoppered with lyo-stoppers, lyophilized and hermetically capped, as described hereinabove.
Example 3
Formulation with pH Adjusted by Citrate Buifer 0.6 grams of the sodium salt of Compound | were dissolved in 12 mL of 0.05M citrate buffer at pH of 6.0. The resulting solution was filtered and 1 mL aliquots were transferred to 10-mL vials, partially stoppered with lyo-stoppers, lyophilized and hermetically capped, as described hereinabove.
B. Stabilization of lyophilized formulation of the sodium salt of Compound | by
Bulking Agents.
In each experiment, formulations of the sodium salt of Compound | and sucrose, at different sucrose/sodium salt of Compound | ratios (TABLE 7), were lyophilized according to standard industry procedures, as described hereinabove.
Formulations 15 to 18 and 19 to 22 were prepared independently for quality control reproducibility purposes. Stability measurements of formulations 19 to 22 were only taken at 12 weeks.
TABLE 7. Composition of formulations
Compound | Sucrose/Compound mg/vial mg/vial Ratio — 5 | s0 | oo | oo — 17 | ss | 5s | = 10 19 | so | oo 21 | s0 | 50 [10
The samples were stored at 40°C for up to 12 weeks. The remaining amount of Compound | was measured by reverse-phase HPLC using gradient solvent method, as described above, and reported as percentage (%) of remaining
Compound I. The results, as set forth in TABLE 8, demonstrate that additions of sucrose at a ratio of 3:1 (sucrose/sodium salt of Compound I) improved stability. A lower sucrose/sodium salt of Compound | ratio of 2:5 sucrose was less desirable.
Stability of formulation with 1:1 ratio was similar to the formulation without sucrose.
TABLE 8. Percent Compound | after 12 weeks at 40°C
Formulation # 1000 | 99.8 | 991 | 990 [ 974 16 | 980 | 977 | 974 | 965 [| 946 17 | 995 | 993 | 987 | 983 | 969 19 | - |= 1 - 1-1] 985 2% | [1 -[- 1 95 et | rr 975 2» oT -[ - 991
An example of solution preparation for the above stability studies of lyophilized formulations are is follows:
Example 4
Formulation with Sucrose 0.4818 grams of the sodium salt of Compound | and 0.1964 grams of sucrose were dissolved in 10 mL of de-ionized water. The resulted solution was filled in 1-mL aliquots in 10-mL vials, partially stoppered with lyo-stoppers and lyophilized, as v3
PCT/iB02/04743 described hereinabove. At the end of the lyophilization cycle, the vials were hermetically capped. :
C. Preservatives.
Generally, preservatives are not required for cephalosporin formulations, including formulations of Compound I. Formulations stored in multi-dose containers versus single dose containers, however, require the addition of preservatives to satisfy antimicrobial effectiveness in vitro. Various formulations prepared in : accordance with the working Examples hereinafter were tested for antimicrobial activity in vitro. Antimicrobial Effectiveness Tests (hereinafter “AET") were performed according to European Pharmacopoeia (EP) Procedures (European Pharmacopoeia, 3d edition, Supplement 201, Council of Europe, Strasbourg) and United States
Pharmacopeia (USP) procedures (U.S. Pharmacopsia, and National Formulary
USP24 NF19, 2000, United States Pharmacopeia Convention Inc., Rockville, MD).
The effectiveness of formulations containing preservatives and the sodium sait of
Compound | is demonstrated in the following examples:
Example 5
AET of the sodium salt of Compound | and methylparaben (1.8 mg/mL)
AET were conducted on a solution containing the sodium salt of Compound
I (80 mg/mL) and methylparaben (1.8 mg/mL) in 20 mM citrate buffer. The results of AET are provided in Table 9. The formulation satisfied USP criteria (see Table 14 for acceptance criteria) for all microorganisms. Furthermore, the formulation o5 satisfied criteria A for all microorganisms, except for S. aureus at 6 and 24 hours time points.
TABLE 9. Log reduction of microbial concentration.
Formulation of the sodium salt of Compound | and Methylparaban [Aspergillusniger | - | - | 506" | 506 [Candidaalbicans __ | - | - | B5A7" | 517
Eco | - | - | 554 | 554 *Corresponds to “no recovery” of microorganisms. 24
AMENDED SHEET
: PCT/IB02/04743
Example 6.
AET of the sodium salt of Compound |,
Methylparaben (1.8 mg/mL) and Propyiparaben (0.2 mg/mL).
AET, according to EP and USP Procedures, were conducted on a solution containing the sodium salt of Compound | (80 mg/mL), methylparaben (1.8 mg/mL) and propylparaben (0.2 mg/mL) in 20 mM citrate buffer. The results of AET are provided in Table 10. The formulation satisfied USP criteria (see Table 14 for ; acceptance criteria) for ail microorganisms. Furthermore, the formulation satisfied
EP criteria A for all microorganisms, except for S. aureus at 6 and 24 hours time points.
TABLE 10. Log reduction of microbial concentration. Formulation of the sodium salt of Compound 1, Methyiparaban and propylparaben.
Aspergilusniger | _- | - | 506 | 506
Candidaabicans | _- | - | 517 | 517
Ecoi | - | - | 5541 554
S.aureus | 006 | 024 | 512 | 52
Example 7.
AET of the sodium salt of Compound | and m-cresol (3 ma/mb.
AET, performed according to EP and USP Procedures, were conducted on a solution of the sodium salt of Compound | (80 mg/mL) and m-cresol (3 mg/mL) prepared by reconstitution of a lyophilized cake of the sodium salt of Compound I with Bacteriostatic Water containing 3mg/mL m-cresol. The results of AET are provided in Table 11. The formulation satisfied USP criteria (see Table 14 for acceptance criteria) for all microorganisms. Furthermore, the formulation satisfied
EP criteria A for all microorganisms, except for S. aureus at 6 hours time point.
TABLE 11. Log reduction of microbial concentration.
Formulation of the sodium salt of Compound | and m-cresol. [Wicroorganism | 6 Hours | 24 Hours [7 Days
Aspergilismiger | __- | - | 4.82"
Candidaalbicans | __- | - | 524"
Ecol | - | - | 541
S.aureus | 1.56 | 4.76 | 561" *Corresponds to “no recavery” of microorganisms. 25
AMENDED SHEET :
Example 8
AET of the sodium salt of Compound |, methylparaben, propylparaben and benzyl alcohol. 5 .
AET, performed according to EP and USP Procedures, were conducted on a solution of the sodium salt of Compound | (80 mg/mL), methylparaben (1.8 mg/mL), propylparaben (0.2 mg/mL) and benzyl alcohol (8.6 mg/mL) and 20mM of citrate buffer, prepared by reconstitution of a lyophilized cake of the sodium salt of
Compound I, methylparaben and propylparaben with bacteriostatic water for injection containing at least 9 mg/mL benyzi alcohol. Methylparaben and propylparaben were included in the lyophilized cake whereas benzyl alcohol was added with bacteriostatic water for injection. The results of AET are provided in
Table 12. The formulation satisfied USP criteria (see Table 14 for acceptance criteria) for all microorganisms. Furthermore, the formulation satisfied EP criteria A for all microorganisms.
TABLE 12. Log reduction of microbial concentration.
Formulation of the sodium salt of Compound |, methylparaben, propylparaben and benzyl alcohol.
Aspergilusniger | __- | - | 48
Candida albicans — - | - | 524
Ecol | - | - | 541
Saureus | 271 | 561 [ 561
Example 9
AEP of the sodium salt of Compound |, m-cresol and methyiparaben.
AET, performed according to EP Procedure, were conducted on a solution _ of the sodium salt of Compound | (80 mg/mL), methylparaben (1.8 mg/mL) and m- cresol (3 mg/mL), prepared by reconstitution of a lyophilized cake of the sodium salt of Compound | with bacteriostatic water for injection containing methylparaben and m-cresol. The results of AET are provided in Table 13. The formulation satisfied EP Criteria A (see Table 14 for acceptance criteria) for S. auereus.
TABLE 13. Log reduction of microbial concentration.
Formulation of the sodium salt of Com ound 1. m-cresol and methylparaben. "5 aureus | 405 | 520
TABLE 14. AET Acceptance Criteria (USP and EP)
Log Reduction
Bacteria EP criteria A 2 3 - -
EP criteria B - 1 3 -
USP cat 1A - - 1.0 3.0
Fungi EP criteria A 2 -
EP criteria B - 1
USP cat 1A NI Ni
NR = no recovery; NI = no increase
European Pharmacopoeia, 3d edition, Supplement 2001, Council of Europe,
Strasbourg; U.S. Pharmacopeia, and National Formulary USP24 NF19, 2000, United
State Pharmacopeial Convention Inc., Rockville, MD.
Claims (26)
1. A lyophilized pharmaceutical composition comprising a compound of Formula |, / NO
H.N N / S 0 Jn [ N= 0] 0) Xie] M+ wherein M" is Na®, Li* or K* ‘and a preservative selected from methy! paraben, propyl paraben and a mixture of methyl and propyl! parabens, wherein the composition has a solution pH in the range of 6.0 to 7.5, for treating or preventing a condition caused by a bacterial infection in dogs and cats.
2. A pharmaceutical composition according to claim 1, wherein M* is Na".
3. A pharmaceutical composition according to claim 1 or 2, further comprising a pharmaceutically acceptable buffer.
4. A pharmaceutical composition according to any one of claims 1to 3, wherein the compound of Formula | is amorphous (6R,7R)-7-{[(2Z)-(2-amino-4- thiazolyl)(methoxyimino) acetylJamino]-8-oxo-3-{(2S)-tetrahydro-2-furanyl}-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt.
5. A pharmaceutical composition according to claim 3 or 4, wherein the buffer is citrate.
6. A pharmaceutical composition according to any one of claims 1 to 5, further comprising a pharmaceutically acceptable bulking agent.
7. A pharmaceutical composition according to claim 6, wherein the bulking agent is selected from sugars, polyalcohols, amino acids, polymers, polysaccharides or inorganic salts.
8. A pharmaceutical composition according to claim 7, wherein the sugars are selected from glucose, maltose, sucrose or lactose: the polyalcohols are sorbitol or mannitol; the amino acid is glycine; the polymer is polyvinylpyrrolidone; the polysaccharide is dextran; and the inorganic salts are sodium or potassium phosphates or sodium chloride. 28 AMENDED SHEET
PCT/IB02/04743
9. A pharmaceutical composition according to any one of claims 1 to 8 wherein the pharmaceutically acceptable preservative is a combination of methyl and propyl parabens.
10. A kit comprising a therapeutically effect amount of a lyophilized pharmaceutical composition comprising a compound | of Formula |; / N—©O HN NAH ¢ TH. o} oo M+ wherein M* is Na*, Li* or K* and a preservative selected from methyl paraben, propyl paraben and a mixture of methyl and propyl parabens, wherein the composition has a solution pH in the range of 6.0 to 7.5; an aqueous pharmaceutically acceptable diluent; and a first and second container means for containing the composition (a) and the diluent (b), wherein the first container is adapted to receive the diluent from the second container.
11. The kit according to claim 10, wherein M" is Na”.
12. The kit according to claim 11 further comprising a pharmaceutically acceptable buffer.
13. Use of a compound of Formula | as defined in claim 10 in the manufacture of a preparation for treating or preventing a condition caused by a bacterial infection in dogs and cats.
14. Use according to claim 13, wherein M" is Na’.
15. Use of the compounds of Formula | as defined in any one of claims 1to 9 inthe manufacture of a preparation for treating or preventing a condition caused by a bacterial infection in dogs and cats. 29 AMENDED SHEET
PCT/IB02/04743
16. Use according to claims 13 to 15, wherein the condition is a skin, soft tissue or urinary tract bacterial infection.
17. Use according to claims 13 to 16, wherein the condition or infection is caused by or complicated by Gram positive or Gram negative bacteria.
18. A substance or composition for use in a method of treating or preventing a condition caused by a bacterial infection in dogs and cats, said substance or composition comprising a compound of Formula | as defined in claim 10, and said method comprising administering to the dog or cat an effective amount of said substance or composition wherein M" is Na“, K” or Li*, effective in preventing such a condition.
19. A substance or composition for use in a method of treatment or prevention according to claim 18, wherein M* is Na”.
20. A substance or composition for use in a method of treating or preventing a condition caused by a bacterial infection in dogs and cats, said substance or composition comprising the compound of Formula | as defined in any one of claims 1 to 9 and said method comprising administering to the dog or cat an effective amount of said substance or composition.
21. A substance or composition for use in a method of treatment or prevention according to claims 18 to 20, wherein the condition is a skin, soft tissue or urinary tract bacterial infection.
22 A substance or composition for use in a method of treatment or prevention according to claims 18 to 21, wherein the condition or infection is caused by or complicated by Gram positive or Gram negative bacteria.
23. A composition according to any one of claims 1 to 9, substantially as herein described with reference to and as illustrated in any of the examples.
24. A kit according to any one of claims 10 to 12. substantially as herein described with reference to and as illustrated in any of the examples. 30 AMENDED SHEET
PCT/IB02/04743
25. Use according to any one of claims 13 to 17, substantially as herein described with reference to and as illustrated in any of the examples.
26. A substance or composition for use in a method of treatment or prevention according to any one of claims 18 to 22, substantially as herein described with reference to and as illustrated in any of the examples. 31 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3853601P | 2001-11-30 | 2001-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200403933B true ZA200403933B (en) | 2006-07-26 |
Family
ID=38181189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200403933A ZA200403933B (en) | 2001-11-30 | 2004-05-20 | Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200403933B (en) |
-
2004
- 2004-05-20 ZA ZA200403933A patent/ZA200403933B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7378408B2 (en) | Methods of treatment and formulations of cephalosporin | |
US7115564B2 (en) | Stable pharmaceutical compositions of dalbavancin and methods of administration | |
ZA200209419B (en) | Glycopeptide phosphonate derivatives. | |
CN110279698B (en) | Ceftolozane antibiotic compositions | |
CN113194943B (en) | Pharmaceutical composition containing cefotaxime sulbactam or cefotaxime tazobactam with stability and antibacterial activity | |
HU229426B1 (en) | Carbapenem antibiotic, composition and method of preparation | |
US5776912A (en) | Lipophilic oligosaccharide antibiotic compositions | |
ZA200403933B (en) | Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs | |
NZ551403A (en) | Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs | |
EP3548059B1 (en) | Combinations of lysobactin and aminoglycosides against diseases caused by gram-positive and gram-negative bacteria in non-human animals | |
US20030149013A1 (en) | Methods of treating bacterial infections in dogs and cats | |
AU2002348985A1 (en) | Methods of treating bacterial infections in dogs and cats | |
US20020161003A1 (en) | Method and compositions for the eradication and control of methicillin-resistant staphylococcus aureus bacteria and the prevention of the development of antibiotic drug resistance in said bacteria | |
ZA200503695B (en) | Methods of administering dalbavancin for treatment of bacterial infections |